In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Agmatine and Imidazolines

Edited by Edited by John E. Piletz (University of Mississippi Medical Center, Jackson, Mississippi), Soundar Regunathan (University of Mississippi Medical Center, Jackson, Mississippi), and Paul Ernsberger (Case Western Reserve School of Medicine, Cleveland, Ohio)
Agmatine and Imidazolines

Published: January 2004

Volume 1009

Learn More

Major developments concerning imidazoline receptor (IR) molecular biology, cell signaling, and purification of endogenous ligands have greatly expanded our understanding of the molecular nature of these proteins and of agmatine-metabolizing enzymes. The diversity of IR subtypes and the possible relationship of these receptors to the function of various organs and potential therapeutic targets in psychiatry and diabetes present new areas for discussion. The diversity of IR subtypes as well as a wide tissue distribution of imidazoline-selective binding sites has led to an appreciation that other organ systems besides the brain are also probably influenced by IR. Furthermore, the discovery and characterization of two endogenous IR ligands (agmatine and harmane) have pointed to the potential therapeutic value of these agents in unexpected areas like brain trauma and psychiatry. Agmatine acts as a neuroprotective agent in brain trauma as well as an agent capable of alleviating chronic pain, drug withdrawal syndromes, and inflammatory responses. This volume serves as a guidepost to these agents' usefulness in other unexpected areas, including diabetes and related metabolic syndromes, drug addiction, and neuropathic pain.